Company

AnewPharma

As of the edition of 20 October 2026, AnewPharma runs 1 drug; it is on route A at 4 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Stopped1
Total1

Where it needs a new molecule

Route A at 4 targets, route B at 0 targets.

Three of its 4 rows, by target and route
TargetRoute
KIT Mast/stem cell growth factor receptor KitRoute A
PDGFRB Platelet-derived growth factor receptor betaRoute A
FLT3 Receptor-type tyrosine-protein kinase FLT3Route A

All 4 rows on route A or B

In the product

4 company-target rows on route A or B; 1 is not shown here, and no score is.

Where its trials are

  • Cancer: 5 trials led
  • Eye: 2 trials led
  • Lungs and airways: 2 trials led